Overview
- Simile announced the round on Thursday, July 30, saying Greenoaks led the $200 million Series B with follow‑on support from Index, Hanabi, Bain Capital Ventures, A*, Factory, Definition and CVS Health Ventures.
- The startup builds AI 'digital twins'—synthetic agents trained on human data that aim to predict emotional reactions and behavior for use in marketing, product research, finance and policy.
- Simile says the new capital will expand model training, compute infrastructure and commercial teams and fund a 'first‑of‑its‑kind' confidence model that predicts the accuracy of each simulation.
- Reporting indicates CVS has piloted the product using initial models seeded by two‑hour interviews with about 1,000 people and tested against roughly 400,000 data points, a method that fuels concerns about inference and linkage risks.
- Investors view the move as a signal that behavioral AI is scaling quickly, but analysts warn the technology can leak sensitive signals, reproduce historical biases and will likely increase calls for auditability and regulatory oversight that affect real customers and patients.